REPLIGEN Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Repligen

Access the complete profile.

Repligen Fast Facts

Revenue	$100 - $500 million    See Exact Annual Revenue
Employees	100 - 500Exact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	3253 Pesticide, Fertilizer & Agricultural Chemical Manufacturing 32541 325414 Biological Product Manufacturing 5417 Scientific Research & Development Services
Address	41 Seyon St Bldg 1 Ste 100 Waltham, MA 02453 www.repligen.com

Repligen's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
• What industry is the company in?

Repligen is a publicly traded company on NMS using the ticker symbol RGEN. Detailed information on company financials and operating reports can be found here: NMS: RGEN

Repligen Annual Revenue and Growth Rate

Repligen	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2018	Details in Premium Report
2017
2016
2015
2014
2013

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Repligen's revenues are gauged from an analysis of company filings.

Investor Activity

Repligen has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.

Date	Investors	Percent Raised	Target Size
June 13, 2019	1	100%	$48 MM
Complete list of funding rounds and total amounts in the Company Report

Trademark Applications

Trademark applications show the products and services that Repligen is developing and marketing. Repligen's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
SPECTRAFLO Laboratory apparatus, namely, molecular separation, purification and dialysis systems and their structural components including dialysis tanks, systems, membranes and tubing	04/18/2019
NGL-IMPACTA Affinity ligands for biological purification purposes	07/02/2018
NGL-IMPACT Affinity ligands for biological purification purposes	06/26/2018

See all trademarks and details in the Full Report.

Recession Risk

Determine whether Repligen grew or shrank during the last recession. This is useful in estimating the financial strength and credit risk of the company. Compare how recession-proof Repligen is relative to the industry overall. While a new recession may strike a particular industry, measuring the industry and company's robustness during the last recession estimates its ability to weather future recessions.

Market Share of Repligen's Largest Competitors

A competitive analysis shows these companies are in the same general field as Repligen, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
TMUNITY THERAPEUTICS	Philadelphia, PA	100
PANACEA BIOMATX	Research Triangle Park, NC	52

Nearby Competitors

These companies are similar in business line and location to Repligen. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
BIOGEN U.S.	Weston, MA	100
SHIRE HOLDINGS US AG	Lexington, MA	73
CUBIST PHARMACEUTICALS	Lexington, MA	7
BIOVERATIV	Waltham, MA	7
AMAG PHARMACEUTICALS	Waltham, MA	4
REPLIGEN	Waltham, MA	1

Future Competition: Repligen's Fastest Growing Competitors

These companies are in the same general field as Repligen and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)